Traders should monitor for potential near-term dilution impact; however, the capital raise strengthens Spyre’s cash position for clinical development. The stock may react negatively short-term due to dilution, but long-term impact depends on pipeline execution.
Price Chart
Executive Summary
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximately $403.0 million in gross proceeds, with an additional $60.5 million option for underwriters to purchase more shares. The offering is expected to close on April 16, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Spyre Therapeutics is offering 6,500,000 shares of common stock at $62.00 per share.
- Gross proceeds are expected to be approximately $403.0 million, before underwriting discounts and expenses.
- Underwriters have a 30-day option to purchase up to an additional $60.5 million worth of shares.
- The offering is expected to close on or about April 16, 2026.
- Jefferies, Goldman Sachs, Evercore ISI, and Guggenheim Securities are joint book-running managers.
Financial Impact
$403.0 million raised, with potential for $463.5 million total if the overallotment is exercised
Risk Factors
- Dilution to existing shareholders from the issuance of new shares
- Market conditions and investor sentiment toward biotech offerings may affect pricing and demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access